Key facts
- Etiome’s last known valuation is $144.0M (Apr 2025).
- It has raised $50.0M; the latest was Early Stage VC ($50.0M) in Apr 2025.
- Notable investors include Flagship Pioneering.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Etiome
- ·The full record, as it builds
Funding rounds
No funding rounds for Etiome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Etiome
Developer of a biostaged medicine designed to map the progression of diseases. The company's technology characterizes disease with increased resolution over time, and medicines are therapies tailored to specific stages of disease, enabling the healthcare industry to intervene at early disease stages and prevent further progression.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 24
- Website
- etiome.bio/
- Ownership
- Privately Held (backing)
Etiome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Etiome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Etiome in its N-PORT filings yet. We sweep new filings monthly.